mAbxience, a majority-owned company of Fresenius with partial ownership from Insud Pharma; and Sandoz , the global leader in affordable medicines, announced a licensing, development, manufacturing and commercialization agreement for an emicizumab biosimilar candidate. The collaboration agreement combines mAbxience's proven development and manufacturing capabilities with Sandoz's global commercial reach, creating a pathway to broaden patient access to this potential high-quality biologic medicine worldwide.
mAbxience will be responsible for the development and manufacturing of the agreed biosimilar through its state-of-the-art GMP-approved facilities in Spain and Argentina, while Sandoz will hold exclusive commercialization rights globally, excluding Argentina, Uruguay, and Paraguay. The financial terms of the agreement remain confidential. The agreement highlights the growing attractiveness of mAbxience's development and manufacturing platform as healthcare systems prepare for a significant wave of biologic medicines losing exclusivity over the coming years.
Jurgen Van Broeck, Chief Executive Officer of mAbxience, said: "This agreement with Sandoz represents a significant recognition of mAbxience's development and manufacturing platform and the expertise of our teams. This agreement combines our capabilities with Sandoz's global biosimilars reach and provides a clear pathway to broaden access to treatment for patients living with hemophilia A. It also reinforces our strategy of combining world-class development and manufacturing capabilities with selected commercial partnerships that can help accelerate patient access to high-quality biologic medicines worldwide."